2023 World Conference on Lung Cancer (Posters)-EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC

EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC - PDF(Slides)

Pdf Summary

This study examined the use of neoadjuvant chemoimmunotherapy in a specific group of patients with stage IB non-small cell lung cancer (NSCLC) of the central type. The current standard treatment for these patients is surgery, which can be associated with complications and lung tissue loss. The study aimed to optimize treatment outcomes by combining neoadjuvant chemoimmunotherapy with modified surgery. <br /><br />The study enrolled 10 male patients with central type squamous cell carcinoma of the lung. These patients underwent neoadjuvant therapy consisting of 2-4 cycles of PD-1 inhibitor combined with chemotherapy, followed by radical resection surgery and lymph node dissection. The median tumor size decreased significantly from 3.2 cm to 0.5 cm after neoadjuvant chemoimmunotherapy. Pathological down-staging was observed in 90% of the patients. The surgical outcomes were favorable, with a 100% R0 resection rate and no grade 3-5 treatment related adverse events or postoperative complications observed.<br /><br />Two representative cases were presented, showing the baseline and preoperative imaging data. These cases demonstrated tumor invasion in the pulmonary artery branches and close proximity to the bronchial orifice. At a median follow-up of 18.7 months, no patient experienced progression, recurrence, or death.<br /><br />In conclusion, neoadjuvant chemoimmunotherapy followed by modified surgery appears to be a feasible treatment option for selected patients with central type stage IB NSCLC. The combination therapy showed favorable safety, efficacy, and long-term survival outcomes in this specific group of patients. Further research and studies are warranted to validate these findings and optimize treatment strategies for NSCLC patients.

Asset Subtitle

Bengang Hui

Meta Tag

Speaker Bengang Hui

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemoimmunotherapy

stage IB non-small cell lung cancer

central type

surgery

complications

lung tissue loss

PD-1 inhibitor

chemotherapy

pathological down-staging

R0 resection rate